Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database

References

• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008;6:109-18
   PubMedGoogle Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
   PubMed Web of Science ®Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymph 2003;44:2069-76
   PubMed Web of Science ®Google Scholar
• Wolff D, Culakova E, Poniewierski MS, et al. Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol 2005;3:24-5
   PubMedGoogle Scholar
• Bonadonna G, Valagussa P. Combined modality approach for high-risk breast cancer. The Milan Cancer Institute experience. Surg Oncol Clin N Am 1995;4:701-14
   PubMedGoogle Scholar
• Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009;101(Suppl1):S18-S22
   Web of Science ®Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Risks, consequences, and new directions for its management. Cancer 2004;100:228-37
   PubMed Web of Science ®Google Scholar
• Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer 2009;101(Suppl1):S23-S6
   Web of Science ®Google Scholar
• Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six european audits of breast cancer treatments. Support Care Cancer 2006;14:901-9
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3199-212
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practices Guidelines in Oncology: Myeloid growth factors Version 1; 2016. http://www.nccn.org/
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Strassels SA, Dickson M, Norris LB, et al. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst 2013;105:1072-3
   PubMedGoogle Scholar
• Calhoun EA, Schumock GT, McKoy JM, et al. Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics 2005;23:767-75
   PubMed Web of Science ®Google Scholar
• Potosky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 2011;103:979-82
   PubMed Web of Science ®Google Scholar
• Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013;368:1131-9
   PubMed Web of Science ®Google Scholar
• Latry P, Molimard M, Begaud B, et al. How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. Eur J Clin Pharmacol 2010;66:743-8
   PubMed Web of Science ®Google Scholar
• De Roquefeuil L. L’échantillon généraliste de bénéficiaires: représentativité, portée et limites. Prat Organ Soins 2009;40:213-23
   Google Scholar
• Pariente A, Pinet M, Moride Y, et al. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf 2010;19:680-6
   PubMed Web of Science ®Google Scholar
• Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012;55:644-53
   PubMed Web of Science ®Google Scholar
• Bongue B, Laroche ML, Gutton S, et al. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system. Eur J Clin Pharmacol 2011;67:1291-9
   PubMed Web of Science ®Google Scholar
• Bocquet F, Paubel P, Fusier I, et al. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis. Appl Health Econ Health Policy 2014;12:315-26
   PubMedGoogle Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Freyer G, Scotte F, Borget I, et al. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010–2011: An analysis of the PMSI database]. Bull Cancer 2016;103:552-60
   PubMed Web of Science ®Google Scholar
• Hadji P, Kostev K, Schroder-Bernhardi D, et al. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther 2012;50:281-9
   PubMed Web of Science ®Google Scholar
• Tjan-Heijnen VC, Biesma B, Festen J, et al. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma. J Clin Oncol 1998;16:2708-14
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632-41
   PubMed Web of Science ®Google Scholar
• Falandry C, Campone M, Cartron G, et al. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 2010;46:2389-98
   PubMed Web of Science ®Google Scholar